Delcath Systems, Inc. — 2016 Q2 Form 10-Q Summary
Business Context and Reporting Period
Delcath Systems, Inc. is a late-stage clinical development and specialty pharmaceutical/medical-device company focused on liver cancers. Its lead product, Melphalan/HDS, is marketed in Europe as the CHEMOSAT Delivery System and remains unapproved for commercial sale in the United States. The filing covers the three and six months ended June 30, 2016.
The company was conducting the global Phase 3 FOCUS trial in hepatic-dominant ocular melanoma and Phase 2 programs in hepatocellular carcinoma and intrahepatic cholangiocarcinoma, while pursuing early European commercialization and reimbursement.
Financial Performance and Position
| Metric | Three Months Ended June 30 | Six Months Ended June 30 |
|---|---|---|
| Revenue | $0.5 million vs. $0.5 million | $0.9 million vs. $0.9 million |
| Gross profit | $0.4 million vs. $0.3 million | $0.6 million vs. $0.6 million |
| Gross margin | 70.6% vs. 70.6% | 70.3% vs. 70.3% |
| Operating loss | $(3.9) million vs. $(3.6) million | $(7.3) million vs. $(7.3) million |
| Net loss | $(6.7) million vs. $(3.7) million | $(8.5) million vs. $(7.2) million |
| Net loss per share | $(4.41) vs. $(4.84) | $(5.72) vs. $(9.96) |
| Cash used in operating activities | Not separately provided | $(7.0) million vs. $(9.0) million |
Second-quarter revenue increased approximately 10% year over year, but first-half revenue declined approximately 3%. Research and development expense increased to $1.9 million in the quarter and $3.3 million year to date, reflecting higher clinical-development investment. Selling, general and administrative expense decreased to $2.3 million in the quarter and $4.7 million year to date.
At June 30, 2016, cash and cash equivalents were $7.5 million, compared with $12.6 million at December 31, 2015. Restricted cash totaled $30.3 million, primarily related to the convertible-note financing. Total assets were $41.4 million and total liabilities were $36.0 million.
Debt, Liquidity, and Capital Structure
- In June 2016, Delcath issued $35.0 million of senior secured convertible notes for $32.2 million of cash proceeds after an 8% original issue discount.
- The notes are secured by a first-priority interest in substantially all company assets, mature December 29, 2017, and bear no ordinary interest. Interest accrues at 15% upon an event of default.
- At June 30, $29.2 million of proceeds remained restricted, subject to release in tranches and specified equity conditions. The balance sheet reported net convertible notes payable of $1.6 million after substantial debt discounts.
- The financing included Series C warrants for approximately 6.8 million shares, exercisable at $4.83 per share at June 30, 2016, with potential additional warrant shares at maturity.
- The warrant liability increased to $31.2 million, largely because of the newly issued warrants. The liability is measured using Level 3 valuation inputs.
- Management stated that existing capital resources were expected to fund operations through the end of 2017, but the filing also disclosed substantial doubt about the company’s ability to continue as a going concern and the likely need for additional capital.
Material Changes Versus the Prior Comparable Period
- Quarterly net loss increased by $3.0 million, or 80%, primarily because of $1.6 million of debt-discount amortization and unfavorable warrant-liability fair-value effects.
- Year-to-date net loss increased by $1.3 million, or 18%, despite lower operating cash usage and lower SG&A expense.
- Research and development spending increased by $0.9 million year to date as clinical programs progressed.
- The company completed a significant secured convertible financing, substantially increasing financing complexity, potential dilution, and default-related risk.
- Warrants excluded from diluted share calculations increased to approximately 7.4 million, compared with approximately 0.1 million in the prior-year period.
- After quarter-end, shareholders approved and Delcath effected a 1-for-16 reverse stock split, increased authorized common shares from 170 million to 500 million, and approved issuance of shares underlying the notes and warrants.
- After quarter-end, Delcath reported that it regained compliance with Nasdaq’s minimum bid-price requirement.
Guidance, Outlook, Commentary, and Risks
No revenue or earnings guidance was provided. Management expects continuing operating losses and significant expenses while it funds clinical development, regulatory activities, and European commercialization. The company believes the June financing supports execution of its development program through the end of 2017.
Key execution priorities include enrollment and conduct of the 240-patient FOCUS trial, Phase 2 HCC/ICC studies, European reimbursement expansion, and clinical adoption of CHEMOSAT. Germany had established a national reimbursement code, but reimbursement rates still required negotiation. UK reimbursement remained uncertain, and NICE had recommended use in a research context.
- Clinical trials may be delayed, unsuccessful, or halted because of safety findings, enrollment, regulatory requirements, manufacturing issues, or changing standards of care.
- Melphalan/HDS has not received U.S. marketing approval. The prior U.S. application received a complete response letter, and approval depends on the new clinical and regulatory program.
- The company has a history of losses, negative operating cash flow, and substantial dependence on additional financing or strategic alliances.
- Convertible-note installments may require cash payment if equity-settlement conditions are not met. Default could trigger 15% interest, redemption premiums, and foreclosure on secured assets.
- Conversion of the notes and exercise of the Series C warrants could cause substantial shareholder dilution; the filing stated that approximately 22.1 million shares were reserved or designated for future issuance at the filing date.
- European sales depend heavily on country-specific reimbursement, hospital adoption, regulatory compliance, and availability of qualified treatment centers.
- Prior clinical experience identified potentially serious risks, including myelosuppression, hepatic injury, severe hemorrhage, gastrointestinal perforation, stroke, and myocardial infarction.
Investor Verification Checklist
- Verify the release schedule and equity conditions governing the $29.2 million of restricted financing proceeds.
- Review the full note and warrant agreements for installment formulas, conversion terms, dilution protections, default provisions, and the potential increase in warrant shares at maturity.
- Track FOCUS trial enrollment, timing, safety data, overall-survival results, and any FDA interactions following the prior complete response letter.
- Assess whether European reimbursement rates and hospital utilization are translating into materially higher CHEMOSAT revenue.
- Reconcile future cash burn and financing needs with management’s stated ability to fund operations through the end of 2017, given the disclosed going-concern uncertainty.
- Monitor warrant-liability revaluations, debt-discount amortization, and their impact on reported earnings and shareholders’ equity.